What is Confo Therapeutics?
Confo Therapeutics operates at the vanguard of medicinal chemistry and structural biology, specializing in the discovery of small molecules and antibodies that target G-protein coupled receptors (GPCRs). These receptors represent a critical class of drug targets, yet they remain notoriously difficult to modulate. Confo's proprietary discovery platform provides a distinct competitive advantage, allowing for the identification of compounds with precise pharmacological profiles. By focusing on these high-value biological targets, the company is well-positioned to address significant unmet medical needs in various therapeutic areas, effectively bridging the gap between fundamental research and clinical application.
How much funding has Confo Therapeutics raised?
Confo Therapeutics has raised a total of $98.4M across 2 funding rounds:
Series A
$33.4M
Series B
$65M
Series A (2019): $33.4M, investors not publicly disclosed
Series B (2024): $65M led by Ackermans & Van Haaren, Driehaus Capital Management, and Quest for Growth
Key Investors in Confo Therapeutics
Ackermans & Van Haaren
A diversified holding company based in Belgium with a long history of supporting growth capital across multiple sectors, including energy and resources.
Driehaus Capital Management
A Chicago-based investment management firm known for its disciplined approach to identifying high-growth opportunities in the public and private markets.
Quest for Growth
A Belgium-based mutual fund that specializes in European growth stocks, with a particular focus on the technology and biotechnology sectors.
What's next for Confo Therapeutics?
With the successful closure of this major enterprise-level funding, Confo Therapeutics is poised to advance its lead candidates through critical clinical milestones. The strategic allocation of these funds will likely prioritize the expansion of its internal pipeline and the enhancement of its discovery platform capabilities. As the company matures, the focus will shift toward establishing high-value partnerships and potentially accelerating the transition of its lead assets into late-stage trials. The involvement of seasoned institutional investors provides not only the necessary financial runway but also the strategic oversight required to navigate the rigorous regulatory and commercial hurdles inherent in the global biotechnology market.
See full Confo Therapeutics company page
